Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company operates across multiple therapeutic areas, with flagship... Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company operates across multiple therapeutic areas, with flagship products including Eylea and Eylea HD for eye diseases such as wet age-related macular degeneration and diabetic macular edema; Dupixent for atopic dermatitis, asthma, and allergic conditions; Libtayo for cutaneous squamous cell carcinoma and other cancers; and Kevzara for rheumatoid arthritis. Regeneron also develops monoclonal and bispecific antibodies through collaborations with partners like Sanofi, and maintains early-stage partnerships in gene editing and RNA interference technologies. The company employs proprietary VelociSuite technologies, including VelocImmune, to accelerate drug development by utilizing genetically humanized mice to produce optimized fully human antibodies. Founded in 1988 and headquartered in Tarrytown, New York, Regeneron serves patients across oncology, immunology, ophthalmology, and cardiovascular disease markets globally.Show lessShow more

Disclosures ESG Data Financial Data

Income Statement Balance Sheet Group Entities

Data not available

Financial Fundamentals data not yet covered for Regeneron Pharmaceuticals

We have not yet reviewed Regeneron Pharmaceuticals's disclosures for Financial Fundamentals data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Regeneron Pharmaceuticals's data?

Start your 30-day free trial to request a data review for Regeneron Pharmaceuticals.

Start Free Trial

Legal Center Contact Us